Bausch Health Companies Inc (TSE:BHC) Director Joseph Papa bought 30,000 shares of the business’s stock in a transaction on Friday, September 13th. The stock was purchased at an average price of C$30.77 per share, with a total value of C$923,076.00. Following the completion of the transaction, the director now directly owns 473,284 shares of the company’s stock, valued at C$14,562,570.05.
BHC traded down C$0.13 during trading on Tuesday, reaching C$30.80. The stock had a trading volume of 410,714 shares, compared to its average volume of 778,753. The firm has a market capitalization of $10.78 billion and a price-to-earnings ratio of -11.84. The company has a quick ratio of 0.73, a current ratio of 1.21 and a debt-to-equity ratio of 906.29. Bausch Health Companies Inc has a 1-year low of C$23.60 and a 1-year high of C$36.52. The stock has a 50 day moving average of C$29.58 and a two-hundred day moving average of C$31.26.
Bausch Health Companies (TSE:BHC) last released its earnings results on Tuesday, August 6th. The company reported C$1.38 earnings per share for the quarter, missing analysts’ consensus estimates of C$1.42 by C($0.04). The business had revenue of C$2.88 billion during the quarter, compared to analysts’ expectations of C$2.89 billion. On average, research analysts forecast that Bausch Health Companies Inc will post 3.7699997 EPS for the current fiscal year.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Featured Article: Are all No-Load Funds Equal?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.